β‐catenin‐controlled tubular cell‐derived exosomes play a key role in fibroblast activation via the OPN‐CD44 axis

S Chen, M Zhang, J Li, J Huang, S Zhou… - Journal of …, 2022 - Wiley Online Library
Tubular injury and peripheral fibroblast activation are the hallmarks of chronic kidney
disease (CKD), suggesting intimate communication between the two types of cells …

Responses to hypoxia: how fructose metabolism and hypoxia-inducible factor-1a pathways converge in health and disease

M Kanbay, A Altıntas, F Yavuz, S Copur… - Current Nutrition …, 2023 - Springer
Abstract Purpose of Review Oxygen is critical for the high output of energy (adenosine
triphosphate) generated by oxidative phosphorylation in the mitochondria, and when oxygen …

[HTML][HTML] Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis

D Chen, Y Niu, F Liu, Y Yang, X Wang, P Li… - Frontiers in …, 2023 - frontiersin.org
Aim: We performed a systematic review and network meta-analysis evaluating the safety
and efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) among …

Long‐term efficacy and safety of hypoxia‐inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta‐analysis including 13,146 …

H Chen, Q Cheng, J Wang, X Zhao… - Journal of clinical …, 2021 - Wiley Online Library
What is known and objective Previous studies based on small‐sample clinical data proved
that short‐term use of hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHD) inhibitors …

[HTML][HTML] The hypoxia response pathway promotes PEP carboxykinase and gluconeogenesis in C. elegans

M Vora, SM Pyonteck, T Popovitchenko… - Nature …, 2022 - nature.com
Actively dividing cells, including some cancers, rely on aerobic glycolysis rather than
oxidative phosphorylation to generate energy, a phenomenon termed the Warburg effect …

[HTML][HTML] Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic …

J Yang, J Xing, X Zhu, X Xie, L Wang… - Frontiers in …, 2023 - frontiersin.org
Objective To compare the effects of five hypoxia-inducible factor-prolyl hydroxylase domain
inhibitors (HIF-PHIs), two erythropoiesis-stimulating agents (ESAs), and placebo on iron …

Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease

P Natale, SC Palmer, A Jaure… - Cochrane Database …, 2022 - cochranelibrary.com
Background Anaemia occurs in chronic kidney disease (CKD) and is more prevalent with
lower levels of kidney function. Anaemia in CKD is associated with death related to …

[HTML][HTML] Efficacy and safety of daprodustat vs rhEPO for anemia in patients with chronic kidney disease: a meta-analysis and trial sequential analysis

Z Fu, X Geng, K Chi, C Song, D Wu, C Liu… - Frontiers in …, 2022 - frontiersin.org
Introduction: Daprodustat, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-
PHI), its efficacy and safety remain unclear. Thus, we conducted this meta-analysis aiming at …

[HTML][HTML] Efficacy and safety of vadadustat for anemia in patients with chronic kidney disease: a systematic review and meta-analysis

L Xiong, H Zhang, Y Guo, Y Song, Y Tao - Frontiers in Pharmacology, 2022 - frontiersin.org
Background: Vadadustat is a novel drug for treating anemia patients with chronic kidney
disease (CKD), but its effect and safety remain uncertain. This study aimed to summarize the …

[HTML][HTML] Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta …

S Ren, X Yao, Y Li, Y Zhang, C Tong… - Frontiers in …, 2023 - frontiersin.org
The objective was to provide a comprehensive summary of existing evidence on the efficacy
and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) for the …